Practical aspects of antiseizure medication treatment in pediatric patients: A helpful guide for pharmacists counseling young patients with epilepsy and their parents
Abstract
Epilepsy is a common brain disorder which frequently affects pediatric patients (from newborns to adolescents). The cornerstone of epilepsy treatment for most patients is the use of antiseizure medicines (ASM). These medications, when used as monotherapy or in combination, can achieve seizure control in up to 70% of patients with epilepsy. However, despite the availability of effective ASMs, adherence to these medicines in pediatric epilepsy tends to be suboptimal, which may adversely affect the long-term prognosis of pediatric patients. In this regard, pharmacist-led interventions, aimed at increasing the health literacy of patients and their family members regarding epilepsy treatment, have been shown to increase adherence to the prescribed ASMs. These interventions focus on educating patients and parents on the nature of epilepsy and practical aspects related to appropriate ASM use. In this article, we aimed to provide a useful source of information for pharmacists (and other healthcare workers) on how to counsel patients and parents on issues related to starting/using ASM treatment (e.g. appropriate dose titration, managing skipped doses), additional measures that may improve treatment outcomes (e.g. monitoring seizure frequency, avoidance of seizure triggers) and safety risks associated with ASMs (and how to control/mitigate these risks).
References
Beghi E. The Epidemiology of Epilepsy. Neuroepidemiology. 2020;54(2):185–91.
Devinsky O, Vezzani A, O'Brien TJ, Jette N, Scheffer IE, de Curtis M, et al. Epilepsy. Nat Rev Dis Primers. 2018;4:18024.
GBD Epilepsy Collaborators. Global, regional, and national burden of epilepsy, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Public Health. 2025;10(3):e203–e227.
Adisu MA, Zemariam AB, Derso YA, Wereta BM, Kassa MA, Kitaw TA, et al. Global patterns and predictors of anti-seizure medication adherence in pediatric epilepsy: A systematic review and meta-analysis. Epilepsy Behav. 2025;172:110544.
Bacci JL, Zaraa S, Stergachis A, Simic G, White HS. Community pharmacists' role in caring for people living with epilepsy: A scoping review. Epilepsy Behav. 2021;117:107850.
Ernawati I, Munif Yasin N, Setyopranoto I, Ikawati Z. The Role of Pharmacists' Interventions in Increasing Medication Adherence of Patients With Epilepsy: A Scoping Review. J Prev Med Public Health. 2024;57(3):212–22.
British Medical Association (BMA), Royal Pharmaceutical Society, Royal College of Paediatrics and Child Health (RCPCH), and Neonatal and Paediatric Pharmacy Group (NPPG). BNF for Children 2022–2023. London: BMJ Group and Pharmaceutical Press; 2022.
Electronic Medicines Compendium (eMC) [Internet]. Datapharm Ltd; c2025 [cited 2025 Aug 15]. Available from: https://www.medicines.org.uk/emc/.
Mediately Baza lekova [Internet]. MODRA JAGODA, spletno oblikovanje in razvoj mobilnih aplikacij d.o.o. [cited 2025 Aug 15]. Available from: https://mediately.co/rs.
Beniczky S, Trinka E, Wirrell E, Abdulla F, Al Baradie R, Alonso Vanegas M, et al. Updated classification of epileptic seizures: Position paper of the International League Against Epilepsy. Epilepsia. 2025;66(6):1804–23.
Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475–82.
Perucca E, French JA, Aljandeel G, Balestrini S, Braga P, Burneo JG, et al. Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper. Epilepsia. 2024;65(3):533–41.
Wirrell EC, Specchio N, Nabbout R, Pearl PL, Riney K. Epilepsy syndromes classification. Epilepsia Open. 2025 Mar 22. doi: 10.1002/epi4.70026. Epub ahead of print.
Devinsky O, Elder C, Sivathamboo S, Scheffer IE, Koepp MJ. Idiopathic Generalized Epilepsy: Misunderstandings, Challenges, and Opportunities. Neurology. 2024;102(3):e208076.
Harriott AM, Tatum WO IV. Electroclinical Syndromes: Adolescent Onset. In: Swaiman KF, Ashwal S, Ferriero DM, Schor NF, Finkel RS, Gropman AL, et al., editors. Swaiman's Pediatric Neurology: Principles and Practice, 6th Edition. Elsevier Inc; 2018; p 576–82.
Hirsch E, French J, Scheffer IE, Bogacz A, Alsaadi T, Sperling MR, et al. ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1475–99.
Nascimento FA, Friedman D, Peters JM, Bensalem-Owen MK, Cendes F, Rampp S, et al. Focal epilepsies: Update on diagnosis and classification. Epileptic Disord. 2023;25(1):1–17.
National Institute of Clinical Excellence. Epilepsies in children, young people and adults (2022). NICE guideline NG217 (Last updated: 30 January 2025).
Tenney JR, Glauser T. Electroclinical Syndromes: Childhood Onset. In: Swaiman KF, Ashwal S, Ferriero DM, Schor NF, Finkel RS, Gropman AL, et al., editors. Swaiman's Pediatric Neurology: Principles and Practice, 6th Edition. Elsevier Inc; 2018; p 569–75.
Asadi-Pooya AA, Sperling MR, editors. Antiseizure Medications: A Clinician’s Manual, 3rd edition. New York (USA): Oxford University Press; 2022.
Kanner AM, Bicchi MM. Antiseizure Medications for Adults With Epilepsy: A Review. JAMA. 2022;327(13):1269-81.
Panayiotopoulos CP. The Epilepsies: Seizures, Syndromes and Management (Chapter 4) [Internet]. In: Principles of Therapy in Epilepsies. Oxfordshire (UK): Bladon Medical Publishing; 2005 [cited 2025 Aug 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2607/.
Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11(9):792–802.
Seiden LG, Connor GS. The importance of drug titration in the management of patients with epilepsy. Epilepsy Behav. 2022;128:108517.
Asadi-Pooya AA, Johannessen Landmark C, Mirzaei Damabi N, Fazelian K. Interactions between antiseizure medications and foods and drinks: A systematic review. Epilepsia Open. 2024;9(2):475–85.
Medicines for children [Internet]. Neonatal and Paediatric Pharmacy Group (NPPG), Royal College of Paediatrics and Child Health (RCPCH) and WellChild. Medicines for Children [cited 2025 Aug 15]. Available from: https://www.medicinesforchildren.org.uk/.
Epilepsy Foundation [Internet]. Epilepsy Foundation; c2025 [cited 2025 Aug 15]. Available from: https://www.epilepsy.com/.
Kasteleijn-Nolst Trenité D, Acharya J, Baumer FM, Beran R, Craiu D, French J, et al. Frequently asked questions and answers on Visually-Provoked (Photosensitive) epilepsy. Epilepsy Behav Rep. 2025;30:100753. doi: 10.1016/j.ebr.2025.100753. PMID: 40230985; PMCID: PMC11995705.
Kim JH, Ha EK, Han B, Han T, Shin J, Chae KY, et al. First-Generation Antihistamines and Seizures in Young Children. JAMA Netw Open. 2024;7(8):e2429654.
Kim H, Kim SH, Kim JB. Antihistamines as a common cause of new-onset seizures: a single-center observational study. Neurol Sci. 2021;42(6):2505–08.
Laccourreye O, Werner A, Giroud JP, Couloigner V, Bonfils P, Bondon-Guitton E. Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants. Eur Ann Otorhinolaryngol Head Neck Dis. 2015;132(1):31–4.
Gidal B, Welty T, Cokley J, Farrell M, Shafer P, Rabinowicz AL, et al. Opportunities for Community Pharmacists to Counsel Patients With Epilepsy and Seizure Clusters to Overcome Barriers and Foster Appropriate Treatment. J Pharm Pract. 2024;37(1):190–7.
Patsalos PN, Spencer EP, Berry DJ. Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. Ther Drug Monit. 2018;40(5):526–48.
Kuyucu S, Caubet JC. Hypersensitivity Reactions to Antiepileptic Drugs in Children: Epidemiologic, Pathogenetic, Clinical, and Diagnostic Aspects. J Allergy Clin Immunol Pract. 2018;6(6):1879–91.e1.
Besag FMC, Vasey MJ. Neurocognitive Effects of Antiseizure Medications in Children and Adolescents with Epilepsy. Paediatr Drugs. 2021;23(3):253–86.
Kanner AM, Helmstaedter C, Sadat-Hossieny Z, Meador K. Cognitive disorders in epilepsy I: Clinical experience, real-world evidence and recommendations. Seizure. 2020;83:216–22.
Besag FMC, Vasey MJ, Sen A. Current evidence for adjunct pyridoxine (vitamin B6) for the treatment of behavioral adverse effects associated with levetiracetam: A systematic review. Epilepsy Behav. 2023;140:109065.
Ulate-Campos A, Fernández IS. Cognitive and Behavioral Comorbidities: An Unwanted Effect of Antiepileptic Drugs in Children. Semin Pediatr Neurol. 2017;24(4):320–30.
Mani R, Monteleone C, Schalock PC, Truong T, Zhang XB, Wagner ML. Rashes and other hypersensitivity reactions associated with antiepileptic drugs: A review of current literature. Seizure. 2019;71:270–8.
Sourbron J, Auvin S, Cabral-Lim L, Devlin A, Dluglos D, Hosny H, et al. Vitamin D prophylaxis in persons with epilepsy? Epilepsia. 2024;65(9):2567–79.
European Medicines Agency. Pharmacovigilance Risk Assessment Committee. Topiramate – referral [Internet]. European Medicines Agency; [cited 2025 Aug 15]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/topiramate#related-medicines.
Hope OA, Harris KM. Management of epilepsy during pregnancy and lactation. BMJ. 2023;382:e074630.
Pack AM, Oskoui M, Williams Roberson S, Donley DK, French J, Gerard EE, et al. Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM. Neurology. 2024;102(11):e209279.
Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16(4):409–31.
Reimers A, Brodtkorb E, Sabers A. Interactions between hormonal contraception and antiepileptic drugs: Clinical and mechanistic considerations. Seizure. 2015;28:66–70.
Serafini A, Gerard E, Genton P, Crespel A, Gelisse P. Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential. CNS Drugs. 2019;33(3):195–208.
